Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Recurrent Multiple Myeloma · Refractory Multiple Myeloma

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Mary Greeley Medical Center, Ames, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-956-4132
    Contact: Principal Investigator (Joseph J. Merchant)
  • McFarland Clinic - Ames, Ames, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · ksoder@mcfarlandclinic.com · 515-239-4734
    Contact: Principal Investigator (Joseph J. Merchant)
  • McFarland Clinic - Boone, Boone, Iowa, United States

  • McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-956-4132
    Contact: Principal Investigator (Joseph J. Merchant)
  • McFarland Clinic - Jefferson, Jefferson, Iowa, United States

  • McFarland Clinic - Marshalltown, Marshalltown, Iowa, United States

    Contact: Study coordinator (Site Public Contact) · 515-956-4132
    Contact: Principal Investigator (Joseph J. Merchant)
  • Tufts Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Site Public Contact) · ContactUsCancerCenter@TuftsMedicalCenter.org · 617-636-5000
    Contact: Principal Investigator (Raymond L. Comenzo)
  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Site Public Contact) · 877-442-3324
    Contact: Principal Investigator (Clifton C. Mo)
  • Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States

    Contact: Study coordinator (Site Public Contact) · coborncancercenter@centracare.com · 877-229-4907
    Contact: Principal Investigator (Donald J. Jurgens)
  • Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Saad Z. Usmani)
  • Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Saad Z. Usmani)
  • Memorial Sloan Kettering Commack, Commack, New York, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Saad Z. Usmani)
  • Memorial Sloan Kettering Westchester, Harrison, New York, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Saad Z. Usmani)
  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Site Public Contact) · 212-639-7592
    Contact: Principal Investigator (Saad Z. Usmani)
  • OhioHealth O'Bleness Hospital, Athens, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • Riverside Methodist Hospital, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • Grant Medical Center, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • Doctors Hospital, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • Grady Memorial Hospital, Delaware, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • Columbus Oncology and Hematology Associates, Dublin, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • Dublin Methodist Hospital, Dublin, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • OhioHealth Mansfield Hospital, Mansfield, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • OhioHealth Marion General Hospital, Marion, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • OhioHealth Pickerington Methodist Hospital, Pickerington, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 614-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • OhioHealth Westerville Medical Campus/Westerville Cancer Center, Westerville, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jennifer.Sexton@ohiohealth.com · 610-788-3860
    Contact: Principal Investigator (Yvonne A. Efebera)
  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Site Public Contact) · ou-clinical-trials@ouhsc.edu · 405-271-8777
    Contact: Principal Investigator (Muhammad Salman Faisal)
  • Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Site Public Contact) · 800-811-8480
    Contact: Principal Investigator (Muhamed Baljevic)
  • Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

    Contact: Study coordinator (Site Public Contact) · cancerinfo@hci.utah.edu · 888-424-2100
    Contact: Principal Investigator (Douglas W. Sborov)
  • Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · WI_research_admin@hshs.org · 920-433-8889
    Contact: Principal Investigator (Anthony J. Jaslowski)
  • Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · wi_research_admin@hshs.org · 920-433-8889
    Contact: Principal Investigator (Anthony J. Jaslowski)
  • Medical College of Wisconsin, Milwaukee, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · 414-805-3666
    Contact: Principal Investigator (Ravi Kishore Narra)
  • ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · research.institute@phci.org
    Contact: Principal Investigator (Timothy R. Wassenaar)
  • ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · 262-928-7878
    Contact: Principal Investigator (Timothy R. Wassenaar)
  • Saint Vincent Hospital Cancer Center at Sheboygan, Sheboygan, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · wi_research_admin@hshs.org · 920-433-8889
    Contact: Principal Investigator (Anthony J. Jaslowski)
  • Sheboygan Physicians Group, Sheboygan, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · wi_research_admin@hshs.org · 920-433-8889
    Contact: Principal Investigator (Anthony J. Jaslowski)
  • Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · oncology.clinical.trials@marshfieldresearch.org · 800-782-8581
    Contact: Principal Investigator (Adedayo A. Onitilo)
  • Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · wi_research_admin@hshs.org · 920-433-8889
    Contact: Principal Investigator (Anthony J. Jaslowski)
  • ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · 262-928-7632
    Contact: Principal Investigator (Timothy R. Wassenaar)
  • UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · Chanda.miller@phci.org · 262-928-5539
    Contact: Principal Investigator (Timothy R. Wassenaar)
  • Marshfield Medical Center - Weston, Weston, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · oncology.clinical.trials@marshfieldresearch.org · 800-782-8581
    Contact: Principal Investigator (Adedayo A. Onitilo)